Krystal Biotech, Inc.
KRYS
$256.33
$6.172.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.02% | 192.00% | 146.22% | 3,734.01% | 423.23% |
| Total Depreciation and Amortization | 67.47% | -3.21% | -65.86% | -9.84% | -59.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.07% | -195.27% | 10.98% | 65.58% | 39.99% |
| Change in Net Operating Assets | 267.80% | -253.20% | 101.48% | -394.16% | 78.25% |
| Cash from Operations | 46.68% | -32.62% | 1,365.09% | 94.92% | 830.68% |
| Capital Expenditure | -167.04% | -62.91% | -68.35% | -392.38% | 56.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 116.03% | 92.24% | 52.69% | -98.22% | -898.16% |
| Cash from Investing | 113.32% | 87.51% | 45.62% | -110.81% | -724.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 546.17% | 10.37% | -83.12% | -90.84% | -7.29% |
| Repurchase of Common Stock | -- | -- | -- | -158.60% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 545.22% | 10.22% | -83.12% | -217.79% | -7.29% |
| Foreign Exchange rate Adjustments | -7.24% | -207.34% | 414.24% | -8.56% | -324.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 456.35% | 37.60% | 440.84% | -5,423.75% | -95.14% |